Saturday 17 October 2026
Export CRIS’s income statement to Excel — free account
Curis, Inc.
CRIS Healthcare Biotechnology
Curis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.4 million, down 13.4% from fiscal 2024. In the quarter to June 2026, revenue fell 66.0%, EPS grew 70.4% and free cash flow fell 20.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.41
0.10
−19.61%
Follow CRIS
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
2 | 4 | 4 | 4 | 5 | 3 | 5 | 4 | 4 | 4 |
P/S ratio |
57.16 | 11.15 | 2.19 | 5.64 | 36.80 | 40.93 | 5.70 | 6.58 | 1.77 | 1.38 |
Altman Z-Score |
(15.64) | (18.08) | (38.41) | (41.44) | (3.32) | (5.75) | (14.89) | (22.30) | (44.90) | (87.83) |
Altman Z″-Score (non-manufacturers) |
(52.48) | (41.63) | (88.73) | (96.16) | (10.44) | (17.95) | (31.95) | (51.01) | (104.16) | (207.55) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(45.84) | (14.71) | (4.63) | (10.08) | (69.76) | (53.34) | (4.72) | (6.47) | (2.08) | (2.05) |
Beneish M-Score |
(4.25) | (2.75) | (2.66) | (3.24) | (2.44) | (2.77) | (2.82) | (3.60) | (2.63) | — |
P/B ratio |
14.70 | 4.60 | 0.00 | 0.00 | 3.05 | 4.80 | 1.24 | 3.35 | 0.00 | 2.39 |
Price to Tangible BV |
21.21 | 7.36 | 0.00 | 0.00 | 3.28 | 5.33 | 1.54 | 6.17 | 0.00 | 0.00 |
EV/Sales |
53.89 | 9.27 | 3.27 | 9.83 | 21.33 | 30.16 | (2.61) | 1.08 | 0.05 | 0.97 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.51 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(11.33) | (1.90) | (1.13) | (3.75) | (8.98) | (8.54) | 0.49 | (0.28) | (0.01) | (0.34) |
EV/FCF |
(11.22) | (1.89) | (1.13) | (3.75) | (8.75) | (8.39) | 0.48 | (0.28) | (0.01) | (0.33) |
Quick Ratio |
3.47 | 4.49 | 2.05 | 3.66 | 17.02 | 8.86 | 8.85 | 2.69 | 1.23 | 0.36 |
Current Ratio |
3.56 | 4.56 | 2.11 | 3.82 | 17.14 | 9.11 | 9.20 | 2.77 | 1.39 | 0.49 |
Net Debt/EBITDA |
0.43 | 0.38 | (0.39) | (1.73) | 6.78 | 2.86 | 1.63 | 1.15 | 0.45 | 0.91 |
Debt/Assets |
34.39% | 56.31% | 94.97% | 178.43% | 0.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.68 | 1.73 | (7.89) | (1.85) | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.10 | 0.15 | 0.19 | 0.28 | 0.09 | 0.06 | 0.08 | 0.11 | 0.18 | 0.31 |
Operating CF/Net income |
0.59 | 0.91 | 0.92 | 0.82 | 0.86 | 0.83 | 0.96 | 0.81 | 0.91 | 3.59 |
Capex/Depreciation |
(1.37) | (0.50) | (0.40) | (0.59) | (3.82) | 0.00 | (0.71) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(20.90) | (12.55) | (7.47) | (5.03) | (4.89) | (9.41) | (11.11) | (23.94) | (72.43) | (2.61) |
| (128.84%) | (200.22%) | (334.15%) | 167.37% | (61.82%) | (41.05%) | (82.58%) | (143.19%) | (634.72%) | 2,829.10% | |
| (79.11%) | (81.06%) | (58.61%) | (88.70%) | (24.98%) | (24.78%) | (41.80%) | (50.95%) | (73.20%) | (24.77%) | |
ROIC |
(781.61%) | (585.03%) | (272.90%) | (189.43%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (890.43%) |
Return on Tangible Assets |
(172.27%) | (105.46%) | (217.49%) | (172.65%) | (18.31%) | (41.52%) | (68.45%) | (120.58%) | (571.74%) | 106.80% |
Average Days of Receivables |
119.24 | 113.32 | 100.25 | 118.36 | 102.51 | 110.50 | 106.86 | 101.75 | 112.06 | 0.00 |
Research and Development Expense of Revenue |
419.69% | 455.61% | 234.11% | 222.93% | 212.90% | 327.58% | 425.87% | 394.05% | 353.52% | 299.21% |
Selling, General and Administrative Expense of Revenue |
207.09% | 142.11% | 141.78% | 115.50% | 111.96% | 162.43% | 193.35% | 186.04% | 153.92% | 148.75% |
Intangible Assets out of Total Assets |
0.16 | 0.12 | 0.24 | 0.26 | 0.04 | 0.06 | 0.08 | 0.12 | 0.22 | 0.45 |
Share Based Compensation of Revenue |
57.46% | 54.14% | 37.78% | 26.57% | 24.90% | 49.57% | 66.44% | 59.86% | 54.34% | 42.55% |
Graham Net Nets |
0.05 | 0.13 | (0.61) | (0.78) | 0.25 | 0.12 | 0.52 | 0.05 | (1.08) | (0.58) |
Graham Number |
0.00 | 0.00 | 702.55 | 1,888.60 | 0.00 | 0.00 | 0.00 | 0.00 | 245.32 | 0.00 |
Earnings Yield |
(13.89%) | (50.00%) | (146.38%) | (57.06%) | (8.18%) | (10.50%) | (98.39%) | (71.97%) | (229.74%) | (120.20%) |
Free Cash Flow Yield |
(8.40%) | (43.97%) | (131.93%) | (46.50%) | (6.63%) | (8.79%) | (94.55%) | (58.94%) | (207.18%) | (211.91%) |
Revenue per Share |
113.36 | 132.68 | 125.94 | 120.53 | 89.03 | 46.52 | 43.52 | 37.87 | 34.60 | 14.35 |
Operating CF per Share |
(539.32) | (648.19) | (363.10) | (315.72) | (211.50) | (164.35) | (232.71) | (145.20) | (125.48) | (41.33) |
Capex per Share |
(4.95) | (2.52) | (1.03) | (0.49) | (5.56) | 0.00 | (1.78) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(544.28) | (650.71) | (364.13) | (316.22) | (217.06) | (164.35) | (234.49) | (145.20) | (125.48) | (41.33) |
Cash per Share |
669.95 | 807.40 | 293.12 | 249.35 | 1,384.50 | 506.26 | 366.69 | 212.82 | 63.42 | 7.69 |
Shareholders Equity per Share |
440.75 | 321.62 | (54.30) | (408.57) | 1,073.71 | 396.27 | 199.37 | 74.31 | (19.02) | 8.30 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
440.75 | 321.62 | (54.30) | (408.57) | 1,073.71 | 396.27 | 199.37 | 74.31 | (19.02) | 8.30 |
Free Cash Flow |
(36.14) | (48.54) | (30.15) | (26.25) | (26.42) | (37.62) | (54.75) | (38.43) | (39.56) | (27.20) |
Working Capital |
34.65 | 50.19 | 14.71 | 18.46 | 162.67 | 108.94 | 82.11 | 38.89 | 7.36 | (7.16) |
Capital Expenditures |
(0.33) | (0.19) | (0.08) | (0.04) | (0.68) | — | (0.42) | — | — | — |
Net Current Asset Value |
19.72 | 14.49 | (13.90) | (44.01) | 99.06 | 50.78 | 29.82 | 3.30 | (20.88) | (7.59) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.04 | 0.02 | 0.01 | 0.00 | 0.06 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.58 | 1.04 | 0.79 | 0.45 | 0.27 | 3.09 | 0.85 | (1.85) | 0.81 | 2.73 |
Cash ROIC |
(38.61%) | (38.59%) | (54.56%) | (53.10%) | (8.80%) | (18.21%) | (41.42%) | (50.57%) | (282.61%) | (258.49%) |
Accounts Receivable Turnover |
3.30 | 3.58 | 3.51 | 3.28 | 3.45 | 3.40 | 3.28 | 3.47 | 3.55 | 0.00 |
Accounts Payable Turnover |
0.08 | 0.09 | 0.14 | 0.14 | 0.12 | 0.10 | 0.05 | 0.07 | 0.03 | 0.01 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
5,381.69 | 3,990.72 | 1,885.94 | 3,240.01 | 2,847.55 | 4,394.38 | 4,534.81 | 5,461.23 | 11,262.86 | 45,519.56 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
2.28 | 2.77 | 2.97 | 3.05 | 3.14 | 3.13 | 3.10 | 2.88 | 3.07 | — |
Average Payables |
5.05 | 5.65 | 4.17 | 3.69 | 4.32 | 5.29 | 4.81 | 3.18 | 3.10 | 4.32 |
Average Assets |
76.36 | 65.78 | 55.58 | 36.24 | 119.73 | 183.33 | 135.57 | 93.07 | 59.27 | 30.62 |
Average Common Equity |
46.89 | 26.63 | 9.75 | (19.20) | 48.38 | 110.69 | 68.63 | 33.11 | 6.84 | (0.27) |
Columns are period end dates